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Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Interferon-
alpha (IFN-α) has recently been recognized to harbor therapeutic potential in the prevention and
treatment of HCC, but it remains controversial as to whether IFN-α exerts direct cytotoxicity against
HCC. Cyclooxygenase-2 (COX-2) is overexpressed in HCC and is considered to play a role in
hepatocarcinogenesis. Therefore, we aimed to elucidate the combined effect of a COX-2 inhibitor,
celecoxib, and IFN-α on in vitro growth suppression of HCC using the hepatoma cell line HLCZ01 and
the in vivo nude mouse xenotransplantation model using HLCZ01 cells. Treatment with celecoxib and
IFN-α synergistically inhibited cell proliferation in a dose- and time-dependent manner. Apoptosis was
identiﬁed by 4',6-diamidino-2-phenylindole dihydrochloride and ﬂuorescent staining. IFN-α upregu-
lated the expression of TRAIL, while celecoxib increased the expression of TRAIL receptors. The
combined regimen with celecoxib and IFN-α reduced the growth of xenotransplanted HCCs in nude
mice. The regulation of IFN-α- and COX-2 inhibitor-induced cell death is impaired in a subset of TRAIL-
resistant cells. The molecular mechanisms of HCC cells resistant to TRAIL-induced apoptosis were
explored using molecular biological and immunological methods. Interferon-α and the COX-2 inhibitorlsevier Inc. This is an open access article under the CC BY-NC-ND license
4.0/).
a; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; IFN-α, interferon-alpha;
entration
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HLCZ01celecoxib synergistically increased TRAIL-induced apoptosis in hepatocellular carcinoma. These data
suggest that IFN-α and celecoxib may offer a novel role with important implications in designing new
therapeutics for TRAIL-resistant tumors.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide, with the majority of cases resulting
from persistent infection with hepatitis B virus (HBV) or hepatitis
C virus (HCV). In particular, chronic HBV infection is a predomi-
nant risk factor for HCC in Asia and Africa [1]. It is the second
most frequent cause of cancer death in men, and it is the sixth
leading cause of cancer death. An estimated 748,300 new HCC
cases and 695,900 cancer deaths occurred worldwide [2]. Half of
these cases and deaths were estimated to occur in China [3].
Hepatic resection, liver transplantation and radiofrequency abla-
tion are increasingly used for the curative treatment of HCC.
However, only about 10–20% of patients with HCC are currently
eligible for surgical intervention. Most patients are still diagnosed
at advanced stages and can only receive palliative treatment [4].
Thus, developing an effective chemoprevention strategy is criti-
cally important, in order to reduce the incidence of this disease.
Interferon-α (IFN-α) has been discovered based on its antiviral
activity [5]. IFN-α belongs to the type I interferon family of cytokines,
originally identiﬁed for their antiviral properties. Further studies
revealed the anti-tumor activity of IFN-n against various tumors via
direct inhibitory effects on tumor cells, anti-angiogenesis, enhanced
immunogenicity of tumors, and immunomodulatory effects [6]. IFN-α
is one of the drugs ﬁrst approved by the FDA for the treatment of
chronic HBV infection, and has been clinically applied for 20 years
[7]. However, patients often develop resistance to IFN-α, and the
mechanisms of resistance are unknown [8]. It is unclear if IFN-α is
directly cytotoxic, and indeed, most hepatoma cell lines are resistant
to IFN-α-mediated apoptosis [9]. Consequently, combination therapy
is necessary to overcome IFN-α resistance.
Overexpression of cyclooxygenase-2 (COX-2) has been asso-
ciated with HCC carcinogenesis [10]. Its inhibitor, celecoxib, leads
to marked growth inhibition of human liver tumor cells, due to
the induction of apoptosis and inhibition of proliferation. Thus,
celecoxib may offer therapeutic and preventive potential in
human hepatocarcinogenesis [11]. Our previous studies have
indicated that the COX-2 inhibitor celecoxib effectively inhibits
the growth and angiogenesis of HepG2 cell xenografts in nude
mice via suppressing the expression of COX-2 [12].
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a member of the TNF superfamily that can initiate
apoptosis through the activation of their death receptors. The ability
of TRAIL to selectively induce apoptosis of transformed or tumor
cells, but not normal cells, promotes the development of TRAIL-
based cancer therapy. Importantly, TRAIL, TRAIL-R1 (DR4), and
TRAIL-R2 (DR5) can all be induced by chemotherapeutics and/or
radiation, which can sensitize cancer cells to TRAIL [13], so TRAIL is
an attractive death ligand in targeted cancer therapy. It triggers
apoptosis via two of its receptors, TRAIL-R1 (DR4) and TRAIL-R2
(DR5). Upon binding of TRAIL or agonistic antibodies to TRAIL-R1 or
TRAIL-R2, death inducing signaling complex (DISC), caspase-8 and
-10 are activated, and may drive the subsequent execution of theapoptotic response through mitochondrial-independent and
mitochondrial-dependent pathways [14]. Thus, understanding the
regulation of the TRAIL apoptosis pathway can help develop more
selective TRAIL-based agents for the treatment of human cancer.
The present study was designed to further explore the underlying
mechanism of combination therapy with IFN-α and the COX-2
inhibitor celecoxib against HCC from the standpoint of the prolifera-
tion inhibition and apoptosis signaling pathway. HBV is thought to be
a main causative agent of most cases of liver cirrhosis, and HCC often
develops in patients with chronic HBV infection. We previously
established a hepatoma cell line, HLCZ01, the ﬁrst cell line supporting
the entire life cycle of both HBV and HCV [15]. Therefore, in this
study, we used HLCZ01 to investigate the mechanism of HCC cells
resistant to the TRAIL-induced apoptosis effect of IFN-α and celecoxib
combination therapy against HCC. Interferon-α and celecoxib syner-
gistically enhanced TRAIL expression-induced apoptosis in hepato-
cellular carcinoma. In conclusion, IFN-α and celecoxib may offer a
novel role with important implications in designing new therapeutics
for TRAIL-resistant tumors.Materials and methods
Reagents and antibody
Recombinant human IFN-α was obtained from Kexing Biotech Co.
Ltd., (Beijing, China). Celecoxib was purchased from Cayman
Chemical (Ann Arbor, MI, USA). Celecoxib was dissolved in dimethyl
sulfoxide (DMSO) and stored at 80 1C. Human recombinant TRAIL
and neutralizing monoclonal anti-TRAIL were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), and PGE2 was purchased
from Cayman Chemical.
HBV infection of cell culture
Human HCC cell line HLCZ01 was grown in Dulbecco's Modiﬁed
Eagle's Medium (DMEM) with 10% fetal bovine serum at 37 1C in 5%
CO2. The supernatant of HepG2.2.15 cells derived from human
hepatoma cell line HepG2 transfected with the full genome of HBV
was collected and ﬁltered. HLCZ01 cells were inoculated overnight
with the ﬁltered supernatant at a multiplicity of infection (MOI) of 20
genome equivalents (Geq) per cell. The cells were washed three times
with PBS, maintained in DMEM/F12 medium, and harvested at the
indicated times. HLCZ01 cells were inoculated with the different
strains of sera from hepatitis B patients diluted at 1:20 and were
cultured for the indicated time periods. The HLCZ01 cells of HBV
infection were isolated and cultured as described previously [15].
Cell growth assay
Cell growth was assessed by MTT assay. Brieﬂy, 5103 cells were
seeded on a 96-well plate in 100 ml of medium and left overnight
to adhere. Subsequently, the medium was replaced with 200 ml of
Table 1 – List of primers used for real-time PCR.
Gene Primer sequences
GAPDH f: 50-TTTGTCAAGCTCATTTCCTG-30
r: 50-TGGTCCAGGGTTTCTTACTC-30
TRAIL f: 50-ACCAACGAGCTGAAGCAGAT-30
r: 50-TCCTTGATGATTCCCAGGAG-30
DR4 f: 50-CAGAACATCCTGGAGCCTGTAAC-30
r: 50-ATGTCCATTGCCTGATTCTTTGTG-30
DR5 f: 50-TGCAGCCGTAGTCTTGATTG-30
r: 50-GCACCAAGTCTGCAAAGTCA-30
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8000 U/ml) and/or celecoxib (0–60 mmol/L), followed by incuba-
tion at 37 1C and 5% CO2 for 48 h. Afterward, HLCZ01 cells were
treated with a single drug or a two-drug combination using the
chosen ﬁxed concentrations for 24 and 48 h. After treatment,
10 ml of MTT solution (5 mg/ml) were added to each well, and the
plates were incubated for another 4 h at 37 1C. After 15 min of
centrifugalization at 2000 rpm, the culture medium was dis-
carded and then was replaced with 150 ml DMSO per well to
dissolve the resultant formazan crystals. Absorbance (A) was
measured spectrophotometrically in a microplate reader (Bio-
Rad, USA) using 570 nm as the test wavelength and 630 nm as the
reference wavelength. Inhibition ratio (%)¼(1-experimental
group A570-630/control group A570-630) 100%. The effect of
soluble TRAIL, TRAIL-neutralizing antibody, and PGE2 on cell
growth was also evaluated.
Flow cytometry analysis
Cell cycle analysis was performed by ﬂow cytometry. DNA
labeling was performed using the Cycletest Plus DNA Reagent
kit (BD Biosciences Pharmingen, San Diego, CA), and the samples
were analyzed using a ﬂow cytometer (BD Pharmingen, San
Diego, CA). For the detection of apoptotic cells, labeling tests
involving both propidium iodide (PI) and annexin-V were per-
formed using an annexin-V staining kit (Invitrogen, USA) accord-
ing to the manufacturer's instructions. The data were analyzed
with CellQuest software.
Caspase activity measurement
Cells were treated with IFN-α and/or celecoxib for the indicated
times in the presence or absence of the different porphyrins
(CoPP, SnPP, ZnPP, 10 mM each) for the indicated times. Caspase-3,
Caspase-8, and Caspase-10 activity were measured in cell lysates
and tissue homogenates. Cells were stimulated with cephalostatin
1 (1 mM) or etoposide (25 mg/ml) for 8 h. Cells (4104) were
centrifuged onto glass slides and dried at room temperature
overnight. Samples were ﬁxed and permeabilized with 4% paraf-
ormaldehyde containing 0.05% saponin in PBS for 15 min at room
temperature. After washing with 0.03% saponin in PBS, probes
were blocked with 1% BSA, 1% FCS, and 0.1% Tween 20 in PBS for
1 h and washed twice in PBS. Release of free 7-amino-4-
triﬂuoromethyl coumarin (AFC) from the synthetic substrate Ac-
DEVD-AFC (50 mM) at 37 1C was determined by ﬂuorescence
measurement in a SpectraFluor Plus plate reader (Tecan, Crail-
sheim, Germany) at an excitation wavelength of 390 nm and an
emission wavelength of 535 nm.
Western blot analysis
Cells were washed twice with PBS and lysed in buffer containing
20 mM Tris–HCl (pH 7.4), 137 mM NaCl, 10% (wt/vol) glycerin, 1%
Triton X-100, 2 mM EDTA, and a protein inhibitor cocktail (Roche)
for 30 min on ice. The homogenate was centrifuged at 14,000 rpm
for 20 min at 4 1C and the supernatants were transferred to fresh
tubes. Protein samples were separated using 10% SDS–polyacry-
lamide gel electrophoresis (SDS–PAGE) and transferred onto a
nitrocellulose membrane. The membranes were blocked in 5%
nonfat dry milk containing 0.1% Tween-20 for 1.5 h at 37 1C, andthen probed with primary antibodies at 4 1C overnight. After
washing, the membranes were incubated with horseradish per-
oxidase (HRP)-conjugated secondary antibody followed by ECL
detection (Amersham Pharmacia Biotech, USA). The membranes
were scanned with a LAS-4000 luminescent image analyzer
(Fujiﬁlm, Japan). Subsequently, the membranes were washed in
20 mM glycine (pH 2.3) and subjected to an anti-tubulin antibody
(Sigma) for equal protein loading. The bound antibodies were
detected by ECL reagent (Pierce, Rockford, IL), according to the
manufacturer's instructions.Real-time reverse PCR
Total cellular RNA was extracted by using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA), according to the manufacturer's instruc-
tions. Real-time RT-PCR for DR4, DR5, TRAIL, and COX-2 was
performed using the ABI PRISM 7700 instrument (Perkin-Elmer
Applied Biosystems, Foster City, CA, USA) with gene-speciﬁc
primers and the SYBR Green I protocol. A total of 1.0 μg RNA
was reverse-transcribed to complementary DNA (cDNA) in a total
volume of 20 μl, and 1 μl of this mixture was used as a template
for Quantitative real-time polymerase chain reaction (RT-PCR).
The primers used for ampliﬁcation are listed in Table 1. Relative
expression ratios normalized to that of GAPDH were calculated.Animal studies
All animal experiments were undertaken in accordance with the
National Institute of Health Guide for the Care and Use of Laboratory
Animals, with the approval of the Hunan Provincial Tumor Hospital
Review Board, Changsha, China, and also following the Hunan
provincial government's Animal Care and Use Committee-approved
protocols. All animals were housed in a virus-free facility and
maintained in a standard temperature- and light-controlled animal
facility. HLCZ01 cells were infected with HBV, and 5106 HLCZ01
cells in 200 μL PBS were injected subcutaneously into the lower right
ﬂank of 6-week-old male BALB/c Nude. Tumor size and body weight
were measured three times weekly, and tumor volumes (mm3) were
evaluated. The values were transformed into tumor size using the
following formula: tumor volume ¼0.5  width2  length. When
the tumor volume reached around 150 mm3, the mice were randomly
divided into four groups (n¼8 each). Celecoxib was suspended in
water with gum arabic and given orally with intubation at a dose of
150mg/kg every day. IFN-αwas intraperitoneally injected at a dose of
5106 U/kg every 3 days until day 24. The mice were sacriﬁced and
tumors were resected and ﬁxed with 10% neutral-buffered formalin,
Fig. 1 – (A) Inhibition of HBV pregenomic RNA transcription in HBV-infected HLCZ01 cells by IFN-α. HBV-infected HLCZ01 cells were
treated with IFN-α. Intracellular viral pregenomic RNA was measured by real-time PCR. The results are the average of three
independent experiments performed in triplicate. *Po0.05, **Po0.01. (B) Detection of DNA fragmentation by DNA ladder assay. SMMC-
7721, Huh7, HLCZ01, and HepG2 cells were exposed to TRAIL for 4 h. Two μg of cellular DNAwas separated on 1% agarose gel at 50 V for
one hour. The data are representative of three independent experiments. (C) Cleaved PARP was detected by Western blot. β-actin was
used as control. The data are representative of two independent experiments. (D) Detection of DR4 and DR5 in SMMC-7721, Huh7,
HLCZ01, and HepG2 cell lines by real-time PCR and Western blot analysis. DR4 or DR5 mRNA were detected by real-time RT-PCR and
normalized with GAPDH, respectively. The results are the average of three independent experiments performed in triplicate. DR4 and
DR5 proteins were detected by Western blot. The data are representative of three independent experiments.
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Tumor sections were determined by immunohistochemistry.TRAIL expression by immunohistochemistry
Immunohistochemical staining was done on formalin-ﬁxed and
parafﬁn-embedded tissue using 5-μm section from tissue microarray
blocks. Mounted tissue section were baked at 60 1C for 30min,
deparafﬁnized in xylene and rehydrated through graded alcohols.
Antigen was retrieved by heating in 1 μM sodium citrate (pH 6.0) in a
pressure cooker for 2 min. According to the manufacturer's instruc-
tions, anti-TRAIL (dilution 1:500) was incubated on the section
overnight at 4 1C after non-speciﬁc staining was blocked, followedby incubation with a horseradish peroxidase-conjugated secondary
antibody. Staining was visualized using DAB chromogen substrate and
counterstained with haematoxylin. The tissue sections were viewed
at 400 magniﬁcation. Three ﬁelds per section were analyzed and
TRAIL-positive cells were calculated using Image-Pro Plus software.DAPI staining
Cells treated with IFN-α (0–6000 IU) and/or celecoxib (0–60 mmol/L)
for 24 h were ﬁxed in 4% paraformaldehyde and incubated in
0.5 μg/mL 4, 6-Diamidino-2-phenylindole (DAPI, Sigma Chemical Co.)
solution for 30min in the dark at room temperature. The cells were
examined by ﬂuorescence microscope.
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Fig. 2 – Inhibitory effects of IFN-α and celecoxib on growth of HLCZ01 cells. HLCZ01 cells were treated with IFN-α or celecoxib for 48 h as
described in Materials and methods. The results showed that IFN-α alone slightly inhibited HLCZ01 cells growth, even when it was used at
a high concentration (6000 IU/mL) (A), and celecoxib as a single agent signiﬁcantly inhibited the growth of HLCZ01 in a dose-dependent
manner (B). (C) HLCZ01 cells were treated with 4000 IU/ml of IFN-α, 40 μM of celecoxib, or the combination of the two agents for 24 and
48 h. There was a synergistic effect when cells were treated with a combination of IFN-α and celecoxib. The experiments were performed
in triplicate. Bars represent means 7 SD; nPo0.05, nnPo0.01.
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All results were reported as mean 7 SD or median (range). The
normality of data distribution was tested by the Kolmogorov–
Smirnov test. Pearson's chi-square test, independent-samples
t-test, nonparametric Mann–Whitney U or Wilcoxon signed ranks
test, logistic regression, and nonparametric Spearman's rank
correlation were used when appropriate. By using the Finner
harmonic mean method and Q-analysis to evaluate the synergistic
effect of the two drugs used in the combination therapy group.
Receiver operating characteristic (ROC) curves were generated to
determine the areas under the ROC curves (AUC) and their 95%
conﬁdence intervals (CI). Data analysis was performed using SPSS
version 16.0 (SPSS, Inc., Chicago, IL, USA). A univariate test was
used to examine the inﬂuence of each clinical variable on survival.
Student's t-test was applied to determine statistical signiﬁcance.
P-values of o0.05 were considered statistically signiﬁcant.Results
The cytotoxic effect of TRAIL on a newly developed HCC
HLCZ01 cell line with HBV infection
To better understand the virus lifecycle and the interaction
between host and virus, we established a novel HCC cell line
HLCZ01 with HBV infection. The cells were derived from well-differentiated HCC tissue of a male patient, and the cells expre-
ssed the human liver-speciﬁc gene and the protein albumin [15].
IFN-α inhibits HBV replication by decreasing the transcription of
viral pregenomic RNA (Fig. 1A). We examined the TRAIL sensitiv-
ity of different human HCC cell lines SMMC-7721, Huh7, HLCZ01,
and HepG2. Cells were exposed to TRAIL and cell death was tested
using DNA ladder assay. DNA ladder was abundantly found in
TRAIL-treated SMMC-7721 and HepG2 cells, while rare in Huh7
and HLCZ01 (Fig. 1B). PARP was cleaved in SMMC-7721 and
HepG2 cells with TRAIL treatment (Fig. 1C). A possible mechanism
of different sensitivity of tested cells to TRAIL-induced apoptosis
could be due to the variable levels of the death receptors resulting
in increased apoptosis signaling in sensitive cells. The functional
TRAIL receptor isoforms (DR4 and DR5) had comparable levels in
TRAIL-sensitive cells compared to TRAIL-resistant cells (Fig. 1D).Anti-tumor effects of IFN-α and celecoxib in HBV-infected
HLCZ01 cells
We evaluated the effects of IFN-α, celecoxib, and combina-
tion therapy on the growth of HLCZ01 cells using the MTT
assay. Treatment with IFN-α alone had a moderately inhibitory
effect and only less than 30% of cell growth inhibition ratio was
achieved, even though a high concentration of IFN-α (6000 IU/mL)
was administered to the cells, indicating that the effect of growth
inhibition of IFN-α as a single agent was not very effective for
HLCZ01 (Fig. 2A). However, the proliferation of celecoxib-treated
Fig. 3 – Cell cycle arrest and apoptosis induced by IFN-α/celecoxib combination therapy in hepatoma cells HLCZ01. (A) DNA content
analysis by ﬂow cytometry showed the percentages of cells in G0/G1, synthetic, or G2/M phases of the cell cycle. The results
demonstrated that the combination therapy apparently induced G0/G1 phase arrest as compared with the single-agent groups.
Representative ﬂow cytometric results are depicted. (B) Apoptosis was detected by ﬂow cytometry. Cells were treated by TRAIL for
4 h, staining with Annexin V conjugated to FITC, which allows the identiﬁcation of apoptotic cells. The combination therapy
further induced apoptosis as compared with IFN-α or celecoxib alone. A representative apoptosis result is presented. All
experiments were performed three times independently. (C) DAPI staining was performed to detect cellular apoptosis.
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achieved in a dose-dependent manner (Fig. 2B). To examine
whether the combination therapy of IFN-α/celecoxib has syner-
gistic effects on cell growth inhibition, the single concentration
for IFN-α and celecoxib was carefully chosen to achieve 20–30% of
inhibition ratio in HLCZ01 cells. The half maximal (50%) inhibitory
concentration (IC) for treatment with IFN-α and celecoxib was
7834.73 IU/mL and 36.17 μM,and the IC50 for the combination
therapy group was 4714.1 IU/mL for IFN-α and 32.61 μM for
celecoxib. Further evaluated the results by Q-analysis, and
obtained the Q value¼0.634(o1), so that the combination
therapy of IFN-α and celecoxib has synergistic effects. Based on
the above results, 4000 IU/mL for IFN-α and 40 μM for celecoxib
were chosen for the concentrations of combination treatment for
subsequent experiments. HLCZ01 cells were exposed to IFN-α,
celecoxib, or a combination of IFN-α and celecoxib for up to 48 h.
A synergistic effect was observed in a time-dependent manner
and more effective inhibition of cell growth was induced in thecombination therapy group in comparison with the single-
therapy groups (Fig. 2C).IFN-α and celecoxib anti-tumor therapy arrests cell cycle
and induces apoptosis in HLCZ01 cells with HBV infection
Since IFN-α and celecoxib have synergistic anti-tumor roles, we
next assessed whether the therapy arrests cell cycle and induces
apoptosis. For understanding the mechanism of growth inhibition,
we investigated the effects of IFN-α and celecoxib on cell-cycle
progression (Fig. 3A). The results of cellular DNA contents distribu-
tion showed an increased accumulation of G0/G1-phase cells in the
combination group, compared to the single-agent groups and no-
treatment control. In parallel, a remarkable decrease of cell popula-
tions at the S phase was induced. The ﬁndings show the synergistic
effect of IFN-α and celecoxib on HLCZ01 cells in inhibiting cell-cycle
progression into DNA synthesis phase.
Fig. 4 – Transcription and expression of DR4, DR5, and TRAIL detected by real-time RT-PCR and Western blotting in hepatoma cell
lines. (A) Cells were treated with IFN-α (4000 IU/mL) and/or celecoxib (40 μM) for 24 h. Expression levels of DR4, DR5, and TRAIL
mRNA were determined by real-time RT-PCR as described in Materials and methods. The expression of each mRNA was normalized
according to the expression levels of housekeeping GAPDH, and the increase of expression in comparison to that of control cells
was calculated. (B) HLCZ01 cells were treated with IFN-α (4000 IU/ml) and/or celecoxib (40 μM) for 24 h, and the expression of each
protein was analyzed by Western blotting.
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Flow cytometric results demonstrated that IFN-α as a single agent
failed to induce apoptosis (10.00%71.64%) in HLCZ01 cells com-
pared with the control group (7.88%71.13%), while celecoxib
resulted in marked apoptosis (17.26%72.37%). The maximum effect
was observed in the combination-therapy group (25.52%73.10%).
There were signiﬁcant differences between the combination-
therapy group and the single-agent groups (Po0.05) (Fig. 3B).
Moreover, the combination of IFN-α and celecoxib also induced a
remarkable increase in cellular apoptosis, detected by DAPI stain-
ing, and an increase in TRAIL expression (Fig. 3C).
Interferon-α and celecoxib synergistically increase TRAIL
expression in HLCZ01 cells with HBV infection
TRAIL is an IFN-targeted gene [16]. However, the underlying reg-
ulatory mechanism has not been explored thus far. Real-time RT-PCR
showed that IFN-α (4000 IU/mL) remarkably increased the levels of
TRAIL mRNA, even at 6 h following treatment with HBV-infected
HLCZ01 cells (Fig. 4A). The levels of DR5 mRNA and DR4 mRNAwere
slightly downregulated in HLCZ01 cells by IFN-α and celecoxib.
Furthermore, the transcription of TRAIL receptors and DR5 mRNA
levels were lowered by IFN-α or celecoxib. Consequently, combina-
tion treatment induced the expression of both TRAIL ligand and
TRAIL receptor. IFN-α and celecoxib increased the expression of DR5and TRAIL, respectively, and combination treatment ampliﬁed both
expressions (Fig. 4B).
Interferon-α- and celecoxib-mediated apoptosis in HLCZ01
cells involves activation of caspases
Treatment of HBV-infected HLCZ01 cells with celecoxib elicited
apoptosis in a dose- and time-dependent manner. To better
understand this process, we investigated whether the activation
of caspase-8 was induced by either IFN-α or celecoxib alone, or by
combination therapy. The caspase-8 activity of HLCZ01 cells with
HBV infection at 24 h after treatment was about 6-fold higher
than that of control cells, followed by the activation of caspase-3.
This observation suggests the involvement of caspases in apop-
tosis induced by IFN-α and celecoxib. Involvement of caspases was
further conﬁrmed by ﬂuorometric determination of the increased
enzymatic activity of the caspase-3 and caspase-8 class of
proteases in HLCZ01 cells following combined treatment with
IFN-α and celecoxib (Fig. 5).
Effects of interferon-α and celecoxib combination therapy
on HLCZ01 cells xenografts in nude mice in vivo
To test whether the synergistic effects of IFN-α and celecoxib have
potentially relevant clinical implications, we next assessed the
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Fig. 6A,B and C, treatment with IFN-α and celecoxib synergisti
cally suppressed tumor growth and reduced tumor weight in vivo.
Examination of the effects of the treatments on tumor cell
proliferation by immunohistochemical staining for TRAIL expressionFig. 5 – Effect of IFN-α and/or celecoxib on caspase-3 and -8
activity in HLCZ01 cells. HLCZ01 cells were treated with IFN-α
(4000 IU/mL) and/or celecoxib (40 μM) for 24 h, followed by a
measurement of the activity of caspase-3 and -8 using a
colorimetric assay kit. Data represent mean7 SD of 6 samples.
*Po0.05, **Po0.01, ***Po0.005 compared with control cells.
Fig. 6 – Combined anti-tumor effects of IFN-α and celecoxib on HC
and treatment with IFN-α or/and celecoxib, tumor formation was
measured at indicated time points, and the statistical signiﬁcance
measured on the day of harvest, after excision of the tumor from t
performed to detect TRAIL expression; Scale bar, 50 lm; *Po0.05,is shown in Fig. 6D. The proportion of TRAIL-positive cells in
the control group was 29.9712.9%, while the percentage
with IFN-α or celecoxib treatment alone was 45.2714.2% and
62.4712.3%, respectively (Po0.05 versus control). Combination
therapy showed a signiﬁcantly greater inhibition of tumor cell
proliferation in comparison with the control and single-therapy
groups (the TRAIL expression was 78.7710.6%; Po0.01 versus
control),and TRAIL expression was negatively correlated with PI
(r¼0.5530, Po0.01). These results imply that treatment with
IFN-α and celecoxib inhibits tumor growth and induces apoptosis of
HCC in vivo.Discussion
Worldwide, over 2 billion people have serological evidence of
HBV, and approximately 360 million individuals are chronic HBV
surface antigen (HBsAg) carriers [17]. Hepatitis B is a main cause
of chronic hepatitis, cirrhosis, and hepatocellular carcinoma [18].
There is no vaccine against HCV, and many patients who are
persistently infected by HBV or HCV do not respond to currently
available therapies [19].C in vivo. (A) HLCZ01 were injected into nude mice for 4 weeks
observed in each groups. (B) Xenografts tumor volume was
was analyzed by two-way ANOVA. (C) Tumor weight was
he euthanized mouse. (D) Immunohistochemistry staining was
**Po0.01.
E X P E R I M E N T A L C E L L R E S E A R C H 3 3 3 ( 2 0 1 5 ) 3 1 6 – 3 2 6324The following mechanisms contribute to the antitumor effect of
IFN-α. First, IFN-α can cause the induction of pro-apoptotic genes.
Second, IFN has direct effects on malignant cells. Third, IFN-α can
inhibit angiogenesis. Last, it can augment antitumor immune
responses and improve liver function [20,21].
Some studies have suggested that COX-2 is an inducible enzyme
frequently found in inﬂammatory tissues and is involved in
carcinogenesis pathways in many organs. It has been reported
that COX-2 expression is correlated with angiogenesis, invasion,
relapse, chemoresistance, and tumorigenesis in HCC [22]. Besides,
a signiﬁcant correlation between COX-2 expression and active
inﬂammation in the adjacent non-cancerous liver tissue is asso-
ciated with shorter disease-free survival in HCC patients [23].
Celecoxib, a selective COX-2 inhibitor and non-steroidal anti-
inﬂammatory drug (NSAID), is widely used for pain and inﬂam-
mation. Celecoxib attenuates Akt phosphorylation and induces
growth inhibition and apoptosis in HCC cells, which can be
partially reversed by ectopic COX-2 expression and PGE2 [24].
The chemopreventive effect of celecoxib has been demonstrated
in animal models of diethylnitrosamine-induced HCC [25].
However, the therapeutic efﬁcacy of IFN-α and celecoxib for HCC
cells with HBV infection has not been tested in immune-competent
animals with orthotopic HBV infecting hepatoma. Therefore, we
used HBV-infected HLCZ01 cells to investigate the mechanism of
combination therapy with IFN-α and celecoxib, a COX-2 inhibitor,
against HCC cells resistant to TRAIL-induced apoptosis.
Our studies from MTT showed that IFN-α and celecoxib acted
synergistically to inhibit HCC. The molecular mechanism behind
this synergy has been explored by some studies. For example, Li
et al. [26] found that aspirin not only signiﬁcantly enhanced IFN-
α-induced antiproliferation and apoptosis of HCC in an in vitro
study, but also enhanced tumor growth inhibition in nude mice.
These ﬁndings suggest a novel strategy of using aspirin to over-
come tumor resistance and enhance the effectiveness of IFN-α in
HCC treatment through activating the STAT1 gene, and have
potential implications for improving future IFN-α protein and
gene therapy. These results are also supported by our own
observation that combined therapy with IFN-α and celecoxib
delayed the cell cycle related to the G0/G1 phase and induced a
marked accumulation of G0/G1-phase cells. In addition to growth
inhibition and cell cycle arrest, the present study also strongly
suggested that IFN-α and celecoxib synergistically induce apop-
tosis of HCC cells. An interesting ﬁnding is that HLCZ01 cells
support the entire lifecycle of HBV, as previous studies did not
show the entire lifecycle of HBV in hepatoma cell lines [27–28]. In
the current study, however, we further conﬁrmed the apoptotic
effects induced synergistically by IFN-α and celecoxib in HBV-
infected HCC cells.
The prognosis of HCC is poor. One of the important factors
affecting survival is resistance to therapeutic agents. Owing to its
speciﬁc toxicity for cancer cells, recombinant TRAIL is among the
most promising apoptosis-based antitumor agents. Therapy based
on TRAIL is now being tested in phase 2 clinical trials in different
types of cancers. However, some HCC cells remain resistant to
TRAIL-induced apoptosis. It has been shown that the death ligand
TRAIL is a critical IFN-induced apoptosis mediator in this scenario
[29]. DR4 and DR5 are the main apoptosis-inducing receptors, and
the receptors have an intracellular death domain to transmit the
apoptotic signal. Herzer et al. [30] reported that IFN-α exhibits
a TRAIL-sensitizing effect in primarily TRAIL-resistant hepatomacell lines. Their research has shown that the TRAIL receptor/ligand
system to IFN-α-induced apoptosis in HCC cells that have acquired
TRAIL resistance may even support tumor progression, and that
IFN-α induced apoptosis through caspase-9 activation.
Kern et al. [31] reported that celecoxib engages different
apoptosis pathways in HCC cells, including the stimulation of
DR4 and DR5 signaling, activation of caspases-3, caspases-8,
caspases-9, and apoptosis originating from mitochondria. TRAIL
is an attractive candidate for future cancer therapies. Several
human carcinomas, including HCC, are resistant to TRAIL when
used as a monotherapy. Recent studies have shown that IFN-α and
celecoxib sensitize HepG2 and Huh7 cells to exogenous TRAIL-
induced apoptosis, and that this sensitization can be achieved
through several mechanisms, such as the upregulation of TRAIL
receptors, activation of caspases-3 and caspases-8 [32]. Our
results showed that exogenous TRAIL, when used alone, could
not effectively suppress cell growth of HLCZ01 cells, while
celecoxib, but not IFN-α, could overcome TRAIL resistance through
DR5 upregulation. The combination of exogenous TRAIL and COX-
2 inhibitors may also be a useful regimen for HCC.
Yano et al. [33] reported that IFN-α induced strong antitumor
effects and the downregulation of IFNAR-2 in HCC cells, and it
decreased tumor volume, weight, and IFNAR-2 in vivo. These data
suggest the potential clinical application of PEG- IFN-α for the
prevention and treatment of HCC. Cao et al. [34] investigated the
in vivo growth inhibitory effects of celecoxib on the HCC cell line
BEL-7402. Athymic nude mice implanted with BEL-7402 cells
were given celecoxib, and the effect of treatment on tumor
growth was evaluated. The results suggest that celecoxib would
be efﬁcacious for the treatment of HCC. Our animal studies have
shown that single treatment with either IFN-α or celecoxib
reduced the growth of xenotransplanted HCCs, and that combined
treatment with IFN-α and celecoxib showed an even stronger
inhibitory effect. Immunohistochemical analysis with DAPI stain-
ing revealed that apoptosis plays a role in the inhibition of
growth. These results underline and strengthen the effect of
combination treatment shown in the in vivo study.
IFN-α has various biological properties, including antiviral res-
ponse, immune modulation, and antiproliferative activity. It has
therefore been widely used for the treatment of chronic hepatitis
viral infections and HCC. IFN-α may prolong survival in some
patients. However, the response is often not satisfactory because
of the limited ability to identify patients who are most likely to
beneﬁt from such targeted adjuvant therapies. HCC cells remain
resistant to IFN-α treatment, and tumor heterogeneity requires
tumor adjuvant therapies [35]. The effects of celecoxib on the
recurrence of adenomas and their modiﬁcation by genetic back-
ground and baseline selenium level remain to be determined [36].
In conclusion, the present study has shown that combination
therapy with IFN-α and celecoxib exerts synergic effects in anti-
proliferation, cell cycle arrest, and apoptosis induction in HLCZ01
cells with HBV infection. In addition, we have demonstrated that
the mitochondrial pathway is involved in the apoptosis of HBV-
infected HLCZ01 cells induced by IFN-α and celecoxib combina-
tion therapy, and that celecoxib sensitizes HBV-infected HLCZ01
cells to IFN-α through upregulating TRAIL expression. Revealing
the mechanisms of IFN-α and celecoxib responsiveness of HCCs
will contribute greatly to establishing better therapeutic strate-
gies for liver tumors and will, thus, enable a more efﬁcient
application of IFN-α in clinical cancer therapy.
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